Parcourir par sujet "natalizumab"
Voici les éléments 1-14 de 14
-
Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab
(2020)Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ... -
Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis
(2018)[No abstract available] -
A comprehensive analysis of antigen-specific antibody responses against human cytomegalovirus in patients with systemic sclerosis
(2019)Anti-human cytomegalovirus (HCMV) antibodies are considered triggers of systemic sclerosis (SSc), but such a hypothesis has been assessed in limited sub-dominant epitopes. Our aim was to systematically assess the potential ... -
The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis
(2015)Importance: A number of officially approved disease-modifying drugs (DMD) are currently available for the early intervention in patients with relapsing-remitting multiple sclerosis (RRMS). The aim of the present study was ... -
Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons
(2016)Purpose To compare the benefits and harms of anti-tumor necrosis factor (TNF)-α and anti-integrin agents as induction and maintenance therapy in adult patients with Crohn's disease. Methods We searched MEDLINE and the ... -
The efficacy of Natalizumab versus Fingolimod for patients with relapsing-remitting multiple sclerosis: A systematic review, indirect evidence from randomized placebo-controlled trials and meta-analysis of observational head-to-head trials
(2016)Background: Although Fingolimod (FGD) and Natalizumab (NTZ) appear to be effective in relapsing-remitting multiple sclerosis (RRMS), they have never been directly compared in a randomized clinical trial (RCT). Methods and ... -
Heterogeneity of Baló’s concentric sclerosis: a study of eight cases with different therapeutic concepts
(2020)Background: Baló’s Concentric Sclerosis (BCS) is a rare heterogeneous demyelinating disease with a variety of phenotypes on Magnetic Resonance Imaging (MRI). Existing literature lacks data especially on the therapeutic ... -
Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
(2021)Background and Objectives: For chronic diseases like multiple sclerosis (MS), real-world evidence on long-term treatment outcomes is essential. The study aimed to provide long-term data on the safety and effectiveness of ... -
Microbiome in multiple sclerosis; where are we, what we know and do not know
(2020)An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study ... -
Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
(2018)Current clinical experience with immunomodulatory agents and monoclonal antibodies in principle has established the benefit of depleting lymphocytic populations in relapsing–remitting multiple sclerosis (RRMS). B and T ... -
Tetracyclines Diminish In Vitro IFN-γ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis
(2021)Introduction: Limited data from clinical trials in multiple sclerosis (MS) reported that minocycline, a widely used antibiotic belonging to the family of tetracyclines (TCs), exerts a beneficial short-lived clinical effect ... -
Thinking outside the ischemia box: Advancements in the use of multiple sclerosis drugs in ischemic stroke
(2021)Ischemic stroke (IS) is a major cause of death and disability, despite early intervention. Thrombo-inflammation, the inflammatory process triggered by ischemia, is a concept that ties IS with multiple sclerosis (MS), under ... -
Transcranial magnetic stimulation (TMS) and repetitive TMS in multiple sclerosis
(2021)Multiple sclerosis (MS) is the most well-known autoimmune disorder of the central nervous system, and constitutes a major cause of disability, especially in young individuals. A wide array of pharmacological treatments is ... -
Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities
(2017)Viruses are directly or indirectly implicated in multiple sclerosis (MS). Here, we review the evidence on the virus-related pathophysiology of MS, introduce common experimental models, and explore the ways in which viruses ...